Securities and Exchange Commission
                             Washington, D.C.  20549



                                    FORM 8-K




                Current Report Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934





        Date of Report (Date of Earliest Event Reported): February 24, 2006




                        Commission File Number:   333-57780



                             INTERCARE DX, INC.
             (Exact name of registrants specified in its charter)

               California                          95-4304537

      (State or other jurisdiction of                (I.R.S. Employer
       incorporation or organization)                Identification No.)


                               6201 Bristol Parkway
                          Culver City California 90230
                       (213) 627-8878 Fax: (310) 743-0581



    (Address, Including Zip Code, And Telephone Number, Including Area Code,
                  Of Registrant's Principal Executive Offices)

































                                        1

SECTION  1.   Registrant's Business and Operations              Not  Applicable

SECTION  2.   Financial  Information                            Not  Applicable

SECTION  3.   Securities and Trading Markets                    Not  Applicable


SECTION  4.   Matters Relating to Accountants and
Financial Statements                                           Not  Applicable

SECTION  5.  Corporate governance and Management               Not  Applicable

SECTION  6.  Reserved                                          Not  Applicable

SECTION  7.  Regulation FD

On February 24, 2006, registrant issued a press release announcing that it has
initiated full  commercialization  of  the  Vasogram  Technology  and  names a
renowned scientist as the chairman of the Scientific Advisory Board.

SECTION  8:  Other Events                                      Not  Applicable

SECTION  9:  Financial Statements and Exhibits                 Not  Applicable

Exhibit 99.1
A Copy of press release announcing that registrant  has initiated full
commercialization of  the  Vasogram  Technology  and names a renowned scientist
as the chairman of the Scientific Advisory Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the  Registrant  has  duly  caused this report to be signed on its behalf by the
undersigned  hereunto  duly  authorized.

                                        InterCare DX,  Inc.
                                          (Registrant)

Date:  February 24, 2006              By:/s/  Anthony  C.  Dike
                                      -------------------------
                                          Anthony  C.  Dike
                                 (Chairman, Chief Executive Officer)































                                        2


Exhibit 99.1

FOR  IMMEDIATE  RELEASE:  FRIDAY  FEBRUARY  24,  2006

CONTACT:     Anthony  C.  Dike,  MD,  Chairman  &CEO
                InterCare  DX,  Inc.
                   213-627-8878
                 www.intercare.com
                 -----------------

INTERCARE DX, INC.  INITIATES FULL COMMERCIALIZATION OF THE  VASOGRAM TECHNOLOGY
AND NAMES A RENOWNED SCIENTIST  AS THE CHAIRMAN OF THE SCIENTIFIC ADVISORY BOARD

CULVER CITY, CALIFORNIA.-Anthony C. Dike, MD, Chairman and CEO of InterCare  DX,
Inc.  (OTC BB: ICCO), announced today the appointment of Emeritus Professor Jeff
Raines,  as  the  Chairman  of  the  Scientific  Advisory Board for the Vasogram
Technology,  which has now been officially introduced to the market after almost
one  year  of pilot testing of the product by InterCare DX, Inc, for patient and
healthcare  providers  acceptance.

Professor Raines, professional experience includes over forty years in academia,
having  received a Doctorate degree in Mechanical Engineering from Massachusetts
Institute  of  Technology  and Doctorate degree in medicine from Harvard Medical
School  under  an  NIH  MD/PhD  Training Fellowship in 1972. He has an extensive
formal  education in the areas of clinical cardiovascular medicine with surgical
exposure,  engineering  and  research. Professor Raines is a  Fellow of American
College  of  Cardiology.  He   has  published   extensively   in   the  area  of
Cardiovascular  medicine.  He  holds  seven  acclaimed  United   States  patents
for  the  Vasogram  and  Endogram  technology.  He  most  recently  retired as a
Professor  of  Surgery  from  University  of  Miami,  Florida,  USA. His role in
InterCare  will  include  working with  the Research and Development division of
InterCare to continue  to  enhance  and  update the Vasogram Technology for both
United   States   and  International commercialization.


"Current  cardiovascular  research  has confirmed that heart attack, stroke, and
most  forms  of  peripheral vascular  disease are caused by abnormalities in the
arterial  wall.  Vasogram  is  a  new  technology  that  has been developed that
allows  physicians  to assess the status of the arterial wall. The test is rapid
and  painless  and  can  be  performed  with no risk in a physician's office. In
addition,  the  cost  of  the  testing  is  competitive  with  other noninvasive
cardiovascular  tests."  Dike  said

"For  the  first time, physicians will know how their patient's arteries compare
to  healthy  subjects  of  the  same gender and age. Further, they will know how
their  patient's arteries compare to subjects with known peripheral and coronary
disease,  which  is  the  direct  cause  of  over  one  million deaths annually,
generating  over $100 billion direct and $180 billion. indirect  treatment costs
annually.

The  Vasogram  technology  will be most helpful in identifying subjects at risk.
With  this  identification treatment will start early and outcomes will improve.
Finally,  this testing will target subjects who will benefit from more expensive
and  perhaps  invasive  testing."  Dike  continued.

Initial  estimates for procedures involving Vasogram technology and total market
opportunity,  as  estimated  by  McKinsey & Company, is between $300 million and
$500  million  of  a  total  $1.4  billion  market  potential.

Potential  users  of  the  Vasogram  Technology include primary care physicians,
cardiologists,  vascular  specialists,  clinics,  and  hospitals."  Dike further
said.

"Professor  Raines  brings  to  InterCare  a wealth of Scientific experience and
contacts,  that  we  believe  will  help InterCare emerge as one of the industry
leaders  in the area of Cardiovascular Technology," said Dike.  "We welcome Jeff
to  InterCare DX family, and know that he will be a tremendous asset as we begin
officially  to  commercialize  the  Vasogram  Technology  worldwide," Dike said.

"I  am  very  thrilled  to  be  working  with Dr. Dike and the InterCare team in
further  developing new technologies in the field of cardiovascular medicine, as
well  as  enhancing  the  Vasogram technology thereby making my Vasogram dream a
reality.'  Said  Professor  Raines

About  InterCare  DX
InterCare  DX,  Inc.  an  affiliate  of  Meridian  Holdings,  Inc.(OTCBB: MRDH),
developed  and  markets  under  an exclusive value-added reseller agreement with
Meridian  Holdings,  Inc., InterCare Clinical Explorer    (ICE ), an innovative,
robust  and  totally  scalable  software application designed to integrate every
aspect  of  the  healthcare  enterprise.  InterCare  provides implementation and
support  for  the  ICE  ,  which  is  used  to  document and track inpatient and
outpatient  diagnoses  and  treatment  modalities  in  various  healthcare
environments,  ranging from individual practices to entire hospital systems. The
Company by initiating commercialization of the Vasogram Technology, will  be one
of  the few technology companies with a unique cardiovascular diagnostics device
in  the  market that is backed by extensive scientific studies and publications.
For  more  information  about  the  company and its products and services, visit
www.intercare.com.
    -------------
NOTE:  Statements  in  this  news  release  that  are  not purely historical are
forward-looking  statements  within the meaning of Section 27A of the Securities
Act  of 1933 and Section 21E of the Securities Exchange Act of 1934 and are made
pursuant  to  the  safe  harbor  provisions of the Private Securities Litigation
Reform  Act of 1995 and any amendments thereto. Material that is forward-looking
may  contain  statements  about  expected future events and/or financial results
that  are  forward-looking  in  nature. Editors and investors are cautioned that
such forward-looking statements invoke risk and uncertainties that may cause the
Company's results to differ from such forward-looking statements. These include,
but  are not limited to, economic, competitive, governmental, technological, and
other  factors  discussed in the statements and/or in the Company's filings with
the  Securities  and  Exchange  Commission.




3